Modality
Fusion Protein
MOA
Menini
Target
TIGIT
Pathway
Angiogenesis
ADPKDNMOSD
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ Oct 2031
Phase 1Current
NCT04306151
1,139 pts·NMOSD
2019-05→2031-10·Completed
NCT08390893
1,706 pts·NMOSD
2020-06→2025-06·Recruiting
2,845 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-0810mo agoPh2 Data· NMOSD
2031-10-105.5y awayPh2 Data· NMOSD
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Complet…
P1/2
Recruit…
Catalysts
Ph2 Data
2025-06-08 · 10mo ago
NMOSD
Ph2 Data
2031-10-10 · 5.5y away
NMOSD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04306151 | Phase 1/2 | NMOSD | Completed | 1139 | HAM-D |
| NCT08390893 | Phase 1/2 | NMOSD | Recruiting | 1706 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |